|
|
News Breaks | | | | November 12, 2012 | | 11:34 EDT |  | ACHN, GILD | Achillion weakness a buying opportunity, says Deutsche Bank
Deutsche Bank says nothing fundamentally has changed with Achillion (ACHN) after Gilead (GILD) reported strong hepatitis C virus data. The firm views the pullback in shares of Achillion as overdone and would be a buyer on the weakness. | |
|
News For ACHN;GILD From The Last 14 Days Check below for free stories on ACHN;GILD the last two weeks. |
|
|
| May 16, 2013 | | 11:50 EDT |  | GILD | Celgene, Gilead lower after new data published at ASCO
 Subscribe for More Information | | | 10:30 EDT |  | ACHN | Achillion management to meet with Maxim
Subscribe for More Information | | | May 15, 2013 | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | 06:06 EDT | | ACHN | Achillion appoints Dr. David Apelian as Chief Medical Officer
Achillion (ACHN) appointed David Apelian, M.D., Ph.D., MBA, to the position of Executive VP and Chief Medical Officer, effective May 28. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfolio of compounds to treat HCV. In addition, Achillion also expanded its clinical operations group with the recent addition of Kevin Kucharski, formerly head of clinical operations at Pharmasset (VRUS), who will serve as Senior VP of Clinical Operations. | | | May 13, 2013 | | 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR | | | May 7, 2013 | | 06:08 EDT |  | ACHN | Achillion reports Q1 EPS (14c), consensus (15c)
Subscribe for More Information | |
|
|
|
|
|
|
